Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" AUPH shares.
View AUPH analyst ratings or view top-rated stocks.

4 equities research analysts have issued 12-month price objectives for Aurinia Pharmaceuticals' stock. Their AUPH share price targets range from $8.00 to $13.00. On average, they expect the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 103.7% from the stock's current price.
View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts.

Aurinia Pharmaceuticals' stock was trading at $8.99 at the beginning of 2024. Since then, AUPH stock has decreased by 45.4% and is now trading at $4.91.
View the best growth stocks for 2024 here.

Aurinia Pharmaceuticals saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 12,240,000 shares, an increase of 14.9% from the March 15th total of 10,650,000 shares. Based on an average daily trading volume, of 2,340,000 shares, the days-to-cover ratio is currently 5.2 days. Currently, 9.6% of the shares of the company are sold short.
View Aurinia Pharmaceuticals' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our AUPH earnings forecast.

Aurinia Pharmaceuticals will be holding an earnings conference call on Thursday, May 2nd at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) issued its earnings results on Thursday, February, 15th. The biotechnology company reported ($0.19) earnings per share for the quarter, missing analysts' consensus estimates of ($0.16) by $0.03. The biotechnology company earned $45.10 million during the quarter, compared to analyst estimates of $45 million. Aurinia Pharmaceuticals had a negative net margin of 44.45% and a negative trailing twelve-month return on equity of 20.10%. The company's quarterly revenue was up 58.8% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.18) earnings per share.

Virtus LifeSci Biotech Products ETF holds 42,195 shares of AUPH stock, representing 1.16% of its portfolio.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Aurinia Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include Sunbelt Securities Inc. (0.13%) and Hennion & Walsh Asset Management Inc. (0.05%). Insiders that own company stock include David RW Jayne, George M Milne Jr, Jill Leversage, Joseph M Miller, Joseph P Hagan, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.